{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:12:16Z","timestamp":1790878336872,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2003100, 2020YFC2003103"],"award-info":[{"award-number":["2020YFC2003100, 2020YFC2003103"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-024-01585-7","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T07:02:04Z","timestamp":1728975724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Plasma lipidomic signatures of dementia with Lewy bodies revealed by machine learning, and compared to Alzheimer's disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Huixin","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"1585_CR1","volume-title":"on the public health response to dementia","author":"Global status report","year":"2021","unstructured":"Global status report. on the public health response to dementia. Geneva: World Health Organization; 2021."},{"key":"1585_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","volume":"3","author":"I McKeith","year":"2004","unstructured":"McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. LANCET NEUROL. 2004;3:19\u201328.","journal-title":"LANCET NEUROL"},{"key":"1585_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. NEUROLOGY. 2017;89:88\u2013100.","journal-title":"NEUROLOGY"},{"key":"1585_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1017\/S0033291713000494","volume":"44","author":"JS Vann","year":"2014","unstructured":"Vann JS, JT O'Brien. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. PSYCHOL MED. 2014;44:673\u201383.","journal-title":"PSYCHOL MED"},{"key":"1585_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jalz.2017.09.014","volume":"14","author":"TJ Ferman","year":"2018","unstructured":"Ferman TJ, Aoki N, Crook JE, Murray ME, Radford NRG, Gerpen JA, et al. The limbic and neocortical contribution of \u03b1-synuclein, tau, and amyloid \u03b2 to disease duration in dementia with Lewy bodies. Alzheimer's Dement. 2018;14:330\u20139.","journal-title":"Alzheimer's Dement"},{"key":"1585_CR6","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. NEUROLOGY. 2005;65:1863\u201372.","journal-title":"NEUROLOGY"},{"key":"1585_CR7","doi-asserted-by":"crossref","unstructured":"Kemp J, Philippi N, Phillipps C, Demuynck C, Albasser T, Martin-Hunyadi C, et al. Cognitive profile in prodromal dementia with Lewy bodies. Alzheimers Res Ther. 2017;9:19.","DOI":"10.1186\/s13195-017-0242-1"},{"key":"1585_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nm.3466","volume":"20","author":"M Mapstone","year":"2014","unstructured":"Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. NAT MED. 2014;20:415\u20138.","journal-title":"NAT MED"},{"key":"1585_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.neurobiolaging.2013.08.001","volume":"35","author":"L Whiley","year":"2014","unstructured":"Whiley L, Sen A, Heaton J, Proitsi P, Garc\u00eda-G\u00f3mez D, Leung R, et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. NEUROBIOL AGING. 2014;35:271\u20138.","journal-title":"NEUROBIOL AGING"},{"key":"1585_CR10","doi-asserted-by":"crossref","unstructured":"Wang J, Wei R, Xie G, Arnold M, Kueider-Paisley A, Louie G, et al. Peripheral serum metabolomic profiles inform central cognitive impairment. SCI REP-UK. 2020;10:14059.","DOI":"10.1038\/s41598-020-70703-w"},{"key":"1585_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.neurobiolaging.2019.10.014","volume":"86","author":"Z Huo","year":"2020","unstructured":"Huo Z, Yu L, Yang J, Zhu Y, Bennett DA, Zhao J. Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis. NEUROBIOL AGING. 2020;86:123\u201333.","journal-title":"NEUROBIOL AGING"},{"key":"1585_CR12","doi-asserted-by":"crossref","unstructured":"Hunsberger HC, Greenwood BP, Tolstikov V, Narain NR, Kiebish MA, Denny CA. Divergence in the metabolome between natural aging and Alzheimer\u2019s disease. SCI REP-UK. 2020;10:19863.","DOI":"10.1038\/s41598-020-68739-z"},{"key":"1585_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/acn3.50956","volume":"7","author":"MM Niedzwiecki","year":"2020","unstructured":"Niedzwiecki MM, Walker DI, Howell JC, Watts KD, Jones DP, Miller GW, et al. High-resolution metabolomic profiling of Alzheimer's disease in plasma. ANN CLIN TRANSL NEUR. 2020;7:36\u201345.","journal-title":"ANN CLIN TRANSL NEUR"},{"key":"1585_CR14","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1038\/tp.2011.55","volume":"1","author":"M Ore\u0161i\u010d","year":"2011","unstructured":"Ore\u0161i\u010d M, Hy\u00f6tyl\u00e4inen T, Herukka S, Sysi-Aho M, Mattila I, Sepp\u00e4nan-Laakso T, et al. Metabolome in progression to Alzheimer's disease. TRANSL PSYCHIAT. 2011;1:e57.","journal-title":"TRANSL PSYCHIAT"},{"key":"1585_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/17460441.2020.1674808","volume":"15","author":"M Cuperlovic-Culf","year":"2020","unstructured":"Cuperlovic-Culf M, Badhwar A. Recent advances from metabolomics and lipidomics application in alzheimer's disease inspiring drug discovery. EXPERT OPIN DRUG DIS. 2020;15:319\u201331.","journal-title":"EXPERT OPIN DRUG DIS"},{"key":"1585_CR16","doi-asserted-by":"crossref","unstructured":"Fu Y, He Y, Phan K, Bhatia S, Pickford R, Wu P, et al. Increased unsaturated lipids underlie lipid peroxidation in synucleinopathy brain. ACTA NEUROPATHOL COM. 2022;10:165.","DOI":"10.1186\/s40478-022-01469-7"},{"key":"1585_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00401-020-02177-z","volume":"141","author":"S Fanning","year":"2021","unstructured":"Fanning S, Selkoe D, Dettmer U. Vesicle trafficking and lipid metabolism in synucleinopathy. ACTA NEUROPATHOL. 2021;141:491\u2013510.","journal-title":"ACTA NEUROPATHOL"},{"key":"1585_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"BD Olsson","year":"2016","unstructured":"Olsson BD, Lautner RM, Andreasson UP, \u00d6hrfelt AP, Portelius EP, Bjerke MP, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. LANCET NEUROL. 2016;15:673\u201384.","journal-title":"LANCET NEUROL"},{"key":"1585_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. NAT MED. 2020;26:379\u201386.","journal-title":"NAT MED"},{"key":"1585_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7:263\u20139.","journal-title":"Alzheimer's Dement"},{"key":"1585_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's Dement. 2018;14:535\u201362.","journal-title":"Alzheimer's Dement"},{"key":"1585_CR22","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S1474-4422(17)30074-1","volume":"16","author":"CD Mueller","year":"2017","unstructured":"Mueller CD, Ballard CP, Corbett AP, Aarsland DP. The prognosis of dementia with Lewy bodies. LANCET NEUROL. 2017;16:390\u20138.","journal-title":"LANCET NEUROL"},{"key":"1585_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/metabo10060229","volume":"10","author":"R Gonz\u00e1lez-Dom\u00ednguez","year":"2020","unstructured":"Gonz\u00e1lez-Dom\u00ednguez R, Gonz\u00e1lez-Dom\u00ednguez \u00c1, Sayago A. \u00c1 Fern\u00e1ndez-Recamales. Recommendations and Best Practices for Standardizing the Pre-Analytical Processing of Blood and Urine Samples in Metabolomics. METABOLITES. 2020;10:229.","journal-title":"METABOLITES"},{"key":"1585_CR24","doi-asserted-by":"crossref","unstructured":"Zhang L, Bi S, Liang Y, Huang L, Li Y, Huang M, et al. Integrated Metabolomic and Lipidomic Analysis in the Placenta of Preeclampsia. FRONT PHYSIOL. 2022;13:807583.","DOI":"10.3389\/fphys.2022.807583"},{"key":"1585_CR25","doi-asserted-by":"publisher","first-page":"108710","DOI":"10.1016\/j.exer.2021.108710","volume":"210","author":"H Wang","year":"2021","unstructured":"Wang H, Zhou Q, Wan L, Guo M, Chen C, Xue J, et al. Lipidomic analysis of meibomian glands from type-1 diabetes mouse model and preliminary studies of potential mechanism. EXP EYE RES. 2021;210:108710.","journal-title":"EXP EYE RES"},{"key":"1585_CR26","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1021\/acs.analchem.7b05395","volume":"90","author":"M Hol\u010dapek","year":"2018","unstructured":"Hol\u010dapek M, Liebisch G, Ekroos K. Lipidomic Anal ANAL CHEM. 2018;90:4249\u201357.","journal-title":"Lipidomic Anal ANAL CHEM"},{"key":"1585_CR27","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1016\/j.chroma.2010.04.034","volume":"1217","author":"R Taguchi","year":"2010","unstructured":"Taguchi R, Ishikawa M. Precise and global identification of phospholipid molecular species by an Orbitrap mass spectrometer and automated search engine Lipid Search. J CHROMATOGR A. 2010;1217:4229\u201339.","journal-title":"J CHROMATOGR A"},{"key":"1585_CR28","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1194\/jlr.R800080-JLR200","volume":"50","author":"N Bartke","year":"2009","unstructured":"Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J LIPID RES. 2009;50:S91\u20136.","journal-title":"J LIPID RES"},{"key":"1585_CR29","doi-asserted-by":"crossref","unstructured":"Hussain G, Wang J, Rasul A, Anwar H, Imran A, Qasim M, et al. Role of cholesterol and sphingolipids in brain development and neurological diseases. LIPIDS HEALTH DIS. 2019;18:26.","DOI":"10.1186\/s12944-019-0965-z"},{"key":"1585_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12017-010-8121-y","volume":"12","author":"MM Mielke","year":"2010","unstructured":"Mielke MM, Lyketsos CG. Alterations of the Sphingolipid Pathway in Alzheimer\u2019s Disease: New Biomarkers and Treatment Targets? NEUROMOL MED. 2010;12:331\u201340.","journal-title":"NEUROMOL MED"},{"key":"1585_CR31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1023\/A:1011603916962","volume":"26","author":"PETTEGREW JW","year":"2001","unstructured":"JW PETTEGREW, K PANCHALINGAM RLHAMILTON, RJ MCCLURE. Brain membrane phospholipid alterations in Alzheimer's disease. NEUROCHEM RES. 2001;26:771\u201382.","journal-title":"NEUROCHEM RES"},{"key":"1585_CR32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.neurobiolaging.2008.05.010","volume":"31","author":"X He","year":"2010","unstructured":"He X, Huang Y, Li B, Gong C, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. NEUROBIOL AGING. 2010;31:398\u2013408.","journal-title":"NEUROBIOL AGING"},{"key":"1585_CR33","first-page":"793","volume":"1841","author":"K Yuyama","year":"2014","unstructured":"Yuyama K, Mitsutake S, Igarashi Y. Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer's disease. Biochim et Biophys Acta (BBA) - Mol Cell Biology Lipids. 2014;1841:793\u20138.","journal-title":"Biochim et Biophys Acta (BBA) - Mol Cell Biology Lipids"},{"key":"1585_CR34","doi-asserted-by":"crossref","unstructured":"Nie Y, Chu C, Qin Q, Shen H, Wen L, Tang Y, et al. Lipid metabolism and oxidative stress in patients with Alzheimer's disease and amnestic mild cognitive impairment.\u00a0BRAIN PATHOL. 2024;34:e13202.","DOI":"10.1111\/bpa.13202"},{"key":"1585_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neurobiolaging.2008.03.011","volume":"31","author":"MM Mielke","year":"2010","unstructured":"Mielke MM, Bandaru VVR, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC. Serum sphingomyelins and ceramides are early predictors of memory impairment. NEUROBIOL AGING. 2010;31:17\u201324.","journal-title":"NEUROBIOL AGING"},{"key":"1585_CR36","doi-asserted-by":"publisher","first-page":"7806","DOI":"10.3390\/ijms23147806","volume":"23","author":"C Tringali","year":"2022","unstructured":"Tringali C, Giussani P. Ceramide and Sphingosine-1-Phosphate in Neurodegenerative Disorders and Their Potential Involvement in Therapy. Int J Mol Sci. 2022;23:7806.","journal-title":"Int J Mol Sci"},{"key":"1585_CR37","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. LANCET NEUROL. 2024;23:178\u201390.","journal-title":"LANCET NEUROL"},{"key":"1585_CR38","doi-asserted-by":"publisher","first-page":"e73094","DOI":"10.1371\/journal.pone.0073094","volume":"8","author":"MM Mielke","year":"2013","unstructured":"Mielke MM, Maetzler W, Haughey NJ, Bandaru VV, Savica R, Deuschle C, et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS ONE. 2013;8:e73094.","journal-title":"PLoS ONE"},{"key":"1585_CR39","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/mds.28652","volume":"36","author":"E Schwedhelm","year":"2021","unstructured":"Schwedhelm E, Englisch C, Niemann L, Lezius S, von Lucadou M, Marmann K, et al. Sphingosine-1\u2010Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK\u2010PD). Mov DISORD. 2021;36:2178\u201382.","journal-title":"Mov DISORD"},{"key":"1585_CR40","doi-asserted-by":"crossref","unstructured":"P\u00e9pin \u00c9, Jalinier T, Lemieux GL, Massicotte G, Cyr M. Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson\u2019s Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model. FRONT PHARMACOL. 2020;11:77.","DOI":"10.3389\/fphar.2020.00077"},{"key":"1585_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2019.05.029","volume":"411","author":"G Vidal-Martinez","year":"2019","unstructured":"Vidal-Martinez G, Najera K, Miranda JD, Gil-Tommee C, Yang B, Vargas-Medrano J, et al. FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces \u03b1-Synuclein Pathology in Parkinsonian GM2 +\/\u2013 Mice. Neuroscience. 2019;411:1\u201310.","journal-title":"Neuroscience"},{"key":"1585_CR42","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/jcb.20097","volume":"92","author":"HL Stunff","year":"2004","unstructured":"Stunff HL, Milstien S, Spiegel S. Generation and metabolism of bioactive sphingosine-1\u2010phosphate. J CELL BIOCHEM. 2004;92:882\u201399.","journal-title":"J CELL BIOCHEM"},{"key":"1585_CR43","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s11064-007-9297-x","volume":"32","author":"P Katsel","year":"2007","unstructured":"Katsel P, Li C. Gene Expression Alterations in the Sphingolipid Metabolism Pathways during Progression of Dementia and Alzheimer\u2019s Disease: A Shift Toward Ceramide Accumulation at the Earliest Recognizable Stages of Alzheimer\u2019s Disease? NEUROCHEM RES. 2007;32:845\u201356.","journal-title":"NEUROCHEM RES"},{"key":"1585_CR44","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.neurobiolaging.2008.05.010","volume":"31","author":"X He","year":"2010","unstructured":"He X, Huang Y, Li B, Gong C, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. NEUROBIOL AGING. 2010;31:398\u2013408.","journal-title":"NEUROBIOL AGING"},{"key":"1585_CR45","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1111\/j.1460-9568.2004.03852.x","volume":"20","author":"Y Huang","year":"2004","unstructured":"Huang Y, Tanimukai H, Liu F, Iqbal K, Iqbal IG, Gong CX. Elevation of the level and activity of acid ceramidase in Alzheimer's disease brain. EUR J NEUROSCI. 2004;20:3489\u201397.","journal-title":"EUR J NEUROSCI"},{"key":"1585_CR46","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1007\/s12035-018-1448-3","volume":"56","author":"K Czubowicz","year":"2019","unstructured":"Czubowicz K, J\u0119\u015bko H, Wencel P, Lukiw WJ, Strosznajder RP. The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer\u2019s Disease and Other Neurodegenerative Disorders. MOL NEUROBIOL. 2019;56:5436\u201355.","journal-title":"MOL NEUROBIOL"},{"key":"1585_CR47","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/mds.25729","volume":"29","author":"SK Abbott","year":"2014","unstructured":"Abbott SK, Li H, Mu\u00f1oz SS, Knoch B, Batterham M, Murphy KE, et al. Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. Mov DISORD. 2014;29:518\u201326.","journal-title":"Mov DISORD"},{"key":"1585_CR48","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cmet.2018.05.019","volume":"28","author":"G Lin","year":"2018","unstructured":"Lin G, Lee P, Chen K, Mao D, Tan KL, Zuo Z, et al. Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to \u03b1-Synuclein Gain. CELL METAB. 2018;28:605\u201318.","journal-title":"CELL METAB"},{"key":"1585_CR49","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease. NEW ENGL J MED. 2009;361:1651\u201361.","journal-title":"NEW ENGL J MED"},{"key":"1585_CR50","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1468-1331.2012.03817.x","volume":"20","author":"KR Kumar","year":"2013","unstructured":"Kumar KR, Ramirez A, G\u00f6bel A, Kresojevi\u0107 N, Svetel M, Lohmann K, et al. Glucocerebrosidase mutations in a Serbian Parkinson's disease population. EUR J NEUROL. 2013;20:402\u20135.","journal-title":"EUR J NEUROL"},{"key":"1585_CR51","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","volume":"137","author":"KE Murphy","year":"2014","unstructured":"Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, et al. Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson\u2019s disease. Brain. 2014;137:834\u201348.","journal-title":"Brain"},{"key":"1585_CR52","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. ANN NEUROL. 2012;72:455\u201363.","journal-title":"ANN NEUROL"},{"key":"1585_CR53","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neulet.2016.10.039","volume":"636","author":"S Pchelina","year":"2017","unstructured":"Pchelina S, Emelyanov A, Baydakova G, Andoskin P, Senkevich K, Nikolaev M, et al. Oligomeric \u03b1-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson\u2019s disease. NEUROSCI LETT. 2017;636:70\u20136.","journal-title":"NEUROSCI LETT"},{"key":"1585_CR54","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s11745-002-0947-6","volume":"37","author":"MM Wright","year":"2002","unstructured":"Wright MM, McMaster CR. PC and PE synthesis: mixed micellar analysis of the cholinephosphotransferase and ethanolaminephosphotransferase activities of human choline\/ethanolamine phosphotransferase 1 (CEPT1). Lipids. 2002;37:663\u201372.","journal-title":"Lipids"},{"key":"1585_CR55","doi-asserted-by":"publisher","first-page":"e17299","DOI":"10.1371\/journal.pone.0017299","volume":"6","author":"D Cheng","year":"2011","unstructured":"Cheng D, Jenner AM, Shui G, Cheong WF, Mitchell TW, Nealon JR, et al. Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS ONE. 2011;6:e17299.","journal-title":"PLoS ONE"},{"key":"1585_CR56","doi-asserted-by":"publisher","first-page":"e0191815","DOI":"10.1371\/journal.pone.0191815","volume":"13","author":"PL Wood","year":"2018","unstructured":"Wood PL, Tippireddy S, Feriante J, Woltjer RL. Augmented frontal cortex diacylglycerol levels in Parkinson's disease and Lewy Body Disease. PLoS ONE. 2018;13:e0191815.","journal-title":"PLoS ONE"},{"key":"1585_CR57","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1093\/brain\/awp293","volume":"132","author":"E Hattingen","year":"2009","unstructured":"Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain. 2009;132:3285\u201397.","journal-title":"Brain"},{"key":"1585_CR58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnagi.2018.00051","volume":"10","author":"D Stoessel","year":"2018","unstructured":"Stoessel D, Schulte C, Teixeira DSM, Scheller D, Rebollo-Mesa I, Deuschle C, et al. Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease. FRONT AGING NEUROSCI. 2018;10:51.","journal-title":"FRONT AGING NEUROSCI"},{"key":"1585_CR59","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nchembio.1750","volume":"11","author":"C Galvagnion","year":"2015","unstructured":"Galvagnion C, Buell AK, Meisl G, Michaels TCT, Vendruscolo M, Knowles TPJ, et al. Lipid vesicles trigger \u03b1-synuclein aggregation by stimulating primary nucleation. NAT CHEM BIOL. 2015;11:229\u201334.","journal-title":"NAT CHEM BIOL"},{"key":"1585_CR60","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1074\/jbc.M114.585703","volume":"290","author":"M Grey","year":"2015","unstructured":"Grey M, Dunning CJ, Gaspar R, Grey C, Brundin P, Sparr E, et al. Acceleration of \u03b1-Synuclein Aggregation by Exosomes. J BIOL CHEM. 2015;290:2969\u201382.","journal-title":"J BIOL CHEM"},{"key":"1585_CR61","doi-asserted-by":"publisher","first-page":"22262","DOI":"10.1074\/jbc.M110.202937","volume":"286","author":"G De Franceschi","year":"2011","unstructured":"De Franceschi G, Frare E, Pivato M, Relini A, Penco A, Greggio E, et al. Structural and Morphological Characterization of Aggregated Species of \u03b1-Synuclein Induced by Docosahexaenoic Acid. J BIOL CHEM. 2011;286:22262\u201374.","journal-title":"J BIOL CHEM"},{"key":"1585_CR62","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1073\/pnas.1601899113","volume":"113","author":"C Galvagnion","year":"2016","unstructured":"Galvagnion C, Brown JWP, Ouberai MM, Flagmeier P, Vendruscolo M, Buell AK, et al. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of \u03b1-synuclein. Proc Natl Acad Sci. 2016;113:7065\u201370.","journal-title":"Proc Natl Acad Sci"},{"key":"1585_CR63","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/1873-3468.12592","volume":"591","author":"S Mizuno","year":"2017","unstructured":"Mizuno S, Sasai H, Kume A, Takahashi D, Satoh M, Kado S, et al. Dioleoyl-phosphatidic acid selectively binds to \u03b1\u2010synuclein and strongly induces its aggregation. FEBS LETT. 2017;591:784\u201391.","journal-title":"FEBS LETT"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01585-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01585-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01585-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:04:30Z","timestamp":1730304270000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01585-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1585"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01585-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Xuanwu Hospital, Capital Medical University (approval No. [2020]141), which complies with the Declaration of Helsinki. Written informed consent was obtained from the patient and their guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}